Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Gilead’s Profit Misses Target; HCV Drug Sales Disappoint

By Drug Discovery Trends Editor | April 29, 2016

Eric Risberg/AP ​Gilead Sciences’s earnings missed analysts’ estimates, tumbling 17 percent in the first quarter. Lower sales of the biotech company’s blockbuster hepatitis C virus (HCV) drugs, Harvoni and Sovaldi, contributed to lower-than-expected profit.

Combined sales of Harvoni and Sovaldi were $4.3 billion in the first quarter of this year, falling short of analysts’ estimates by nearly $300 million and dropping $600 million below the previous quarter, Gilead reported on Thursday.

The drug maker attributed this decline to discounts given to private insurers and higher rebates for patients in health plans, like Medicaid. The HCV drugs are priced at $84,000, for Sovaldi, and $94,500, for Harvoni, for a full-course treatment.

Gilead shares dropped more than 6 percent as the biotech company posted earnings of $3.03 a share, and near $8 billion in revenue. Analysts had predicted Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.

During the first quarter, Gilead’s HCV drugs Harvoni and Sovaldi had $3.02 billion and $1.28 billion in sales, respectively. Analysts expected $3.13 billion and $1.37 billion in sales, according to estimates.

Gilead said it expects U.S. sales of its HCV drugs to remain flat this year. AbbVie and Merck currently offer similar treatments, bolstering competition.

Gilead’s stock fell 5.7 percent to $91.50 in after-hours trading Thursday.

Details of the company’s revenue:

  • Gilead’s sales from last quarter, including its HCV drugs, were $7.7 billion
  • Gilead raised its dividend 9.3 percent to 47 cents a share
  • Product sales slumped in the U.S. by $800 million versus last year, following the approval of Merck’s Zepatier in January. Last year, U.S. product sales were $5.2 billion; this time, they were $4.4 billion.
  • Sales surged in Japan, reaching $1.1 billion

  • Filed Under: Drug Discovery

     

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50